Stock 1SXP SCHOTT PHARMA AG & CO. KGAA
Add to a list
To use this feature you must be a member
Log inSign up

All News SCHOTT Pharma AG & Co. KGaA Deutsche Boerse AG

Equities

1SXP

DE000A3ENQ51

Market Closed - Deutsche Boerse AG
Other stock markets
 11:00:15 2024-05-31 am EDT 		5-day change 1st Jan Change
29.28 EUR +3.24% Intraday chart for SCHOTT Pharma AG & Co. KGaA -4.00% -13.37%
May. 28 SCHOTT PHARMA : Berenberg reiterates its Neutral rating ZD
May. 21 Deutsche Bank Research lowers target for Schott Pharma - 'Buy' DP

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SCHOTT PHARMA : Berenberg reiterates its Neutral rating
ZD
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
Deutsche Bank Research lowers target for Schott Pharma - 'Buy'
DP
SCHOTT PHARMA : Receives a Buy rating from Deutsche Bank
ZD
UBS lowers target for Schott Pharma to 33 euros - 'Neutral'
DP
SCHOTT PHARMA : UBS reiterates its Neutral rating
ZD
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQ
Barclays lowers Schott Pharma target to 25 euros - 'Equal Weight'
DP
SCHOTT PHARMA : Deutsche Bank reiterates its Buy rating
ZD
SCHOTT PHARMA : Barclays remains Neutral
ZD
Schott Pharma falls sharply - 'High dependence on end markets'
DP
SCHOTT PHARMA : Gets a Neutral rating from UBS
ZD
Schott Pharma warns of weak syringe sales - share price slide
DP
Schott Pharma falls sharply
DP
SCHOTT PHARMA : Jefferies reiterates its Neutral rating
ZD
Schott Pharma warns of weak syringe sales in the coming year
DP
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
EQ
SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1SXP Stock
  4. 1SXP Stock
  5. News SCHOTT Pharma AG & Co. KGaA